5 March 2021 - - An Investigational New Drug application of the phase III clinical trial of Proxalutamide's treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration, China-based Kintor Pharmaceutical Ltd. (HKEX: 9939) said.

Kintor has been the first China-based biopharma company whose small-molecule novel drug was granted with a phase III clinical trial approval by the FDA for the treatment of COVID-19.

Founded in 2009, Kintor Pharmaceuticals aims to become a leading enterprise in the R and D and commercialization of "best-in-class" and "first-in-class" innovative therapies.

The company initially focused on androgen receptor related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as COVID-19, prostate cancer, breast cancer, liver cancer,hair loss and acne.

Kintor Pharmaceuticals has prospectively developed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including five products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as PD-L1/TGF-β dual-targeting antibody, AR-Degrader and c-Myc inhibitors that are undergoing preclinical research.

Globally, the company has more than 60 issued patents or under review, many of which are listed as the "Major New Drugs Discovery" in National 12th and 13th Five-Year Plans.